Andac Salman1, Eren Cerman2, Dilek Seckin1, Metin Kanitez3. 1. Marmara University School of Medicine, Department of Dermatology, Istanbul, Turkey; 2. Marmara University School of Medicine, Department of Ophthalmology, Istanbul, Turkey; 3. Marmara University School of Medicine, Department of Oncology, Istanbul, Turkey.
Abstract
BACKGROUND: Erlotinib is a targeted anti-cancer drug which acts through the inhibition of epidermal growth factor receptor (EGFR). MAIN OBSERVATIONS: A 79-year-old developed bilateral ectropion after he received erlotinib treatment for lung adenocarcinoma. The ectropion completely resolved with symptomatic treatment without any modification in erlotinib therapy. CONCLUSIONS: EGFR inhibitors are frequently associated with a variety of mucocutaneous adverse events. Ocular toxicity associated with these agents has been reported rarely. We present this case to underline the importance of recognition of newly reported cutaneous and ocular adverse events of targeted therapies.
BACKGROUND:Erlotinib is a targeted anti-cancer drug which acts through the inhibition of epidermal growth factor receptor (EGFR). MAIN OBSERVATIONS: A 79-year-old developed bilateral ectropion after he received erlotinib treatment for lung adenocarcinoma. The ectropion completely resolved with symptomatic treatment without any modification in erlotinib therapy. CONCLUSIONS:EGFR inhibitors are frequently associated with a variety of mucocutaneous adverse events. Ocular toxicity associated with these agents has been reported rarely. We present this case to underline the importance of recognition of newly reported cutaneous and ocular adverse events of targeted therapies.
Authors: Yevgeniy Balagula; Claus Garbe; Patricia L Myskowski; Axel Hauschild; Bernardo L Rapoport; Christine B Boers-Doets; Mario E Lacouture Journal: Int J Dermatol Date: 2011-02 Impact factor: 2.736
Authors: Andrew S Eiseman; Joseph C Flanagan; Alfred B Brooks; Edith P Mitchell; Clifford H Pemberton Journal: Ophthalmic Plast Reconstr Surg Date: 2003-05 Impact factor: 1.746
Authors: Alejandro Saint-Jean; Maite Sainz de la Maza; Merce Morral; Josep Torras; Ramon Quintana; Juan Jose Molina; Nicolas Molina-Prat Journal: Ophthalmology Date: 2012-05-12 Impact factor: 12.079